FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – USA – 06/2024”.
The Monitor is a month-to-month printed overview of enterprise capital traits within the US Healthcare & Life Sciences sector.
As of the top of June 2024 we recognized the next present VC traits in the USA:
- Complete Healthcare & Life Sciences funding reached EUR 18,355m
- Biotech obtained 53% of the overall funding quantity (EUR 9,700m) with oncology being the main indication (26%)
- TechBio is likely one of the strongest progress segments securing 11% of the overall YTD funding quantity
- In June Formation Bio secures the best transaction quantity with EUR 345m, adopted by Enveda Biosciences with EUR 161m and Marea Therapeutics with EUR 148m
- ARCH Enterprise Companions (United States) is essentially the most energetic investor (by deal quantity), adopted by RA Capital Administration (United States) and GV (Google Ventures / United States)
To entry the total report, please click on right here.
By Mathias Klozenbücher und Johannes Hyperlink